<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20171218037936N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-03-05</date_registration>
      <primary_sponsor>Oroumia University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of probiotics on late-onset sepsis in very preterm newborns</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of probiotics on late-onset sepsis in very preterm newborns</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2017-02-19</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>84</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29386</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: randomization will be as balanced (permuted) block randomization. Sample size was determined based on previous studies with respect to d = 10% and P = 0.7 and α = 0.05 in each group of 42 people in a total of 84 people. According to the sample size, and block size of 6 (AAABBB), 14 blocks will be selected. Initially, all possible six-point permutations will be listed, and then each  will be assigned a code, and in the sequel, 14 of these codes will be selected as lotteries, followed by the corresponding combinations with each of the selection codes Listed and individuals will be assigned to the corresponding groups, Blinding description: The groups under study are two groups .The probiotic will be used for  intervention group and placebo for the control group. Each participant will be assigned a code that will remain secret until the end of the study. To ensure that the type of substance received are not identified, a placebo and  probiotic substance will be provided in one form and in the same vials .</study_design>
      <phase>3</phase>
      <hc_freetext>late-onset sepsis in very preterm infants.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 42 preterm infants with a gestational age of less than 32 weeks and a weight of between 1,000-1,500 g and matched with clinical inclusion criteria for the study  randomly assigned and recived one drop  per kilogram of body weight of probiotic(Pedilact droplet of Zist takhmir Company) solution twice daily. Intervention 2: Control group: 42 preterm infants with a gestational age of less than 32 weeks and a weight of between 1,000-1,500 g and matched with clinical inclusion criteria for the study randomly assigned and recived one drop  per kilogram of body weight of Dish water twice daily.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data forms potentially can be shared after unidentifiable individuals.

When:
The access period start one year after the print results

To whom:
Only for researchers working in academic and academic institutions

Conditions:
In the case of scientific authentication, information will be provided to them

Where to obtain:
Dr. Siamak Karimi’s Email( Pediatric Resident)
siamack.karimi@gmail.com

How to obtain:
Upon receipt of the email, the request will be contacted by the applicant

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Siamack Karimi Heydarabad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahhari hospital, Kashani Av Urmia  Vest Azarbaijan  Iran, Islamic Republic Of</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>57147</zip>
        <telephone>+98 44 3223 7078</telephone>
        <email>siamack.karimi@gmail.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr Kamran Dehghan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Motahhari hospital, Kashani Av Urmia, Vest Azarbaijan  Iran, Islamic Republic Of</address>
        <city>Urmia</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>57147</zip>
        <telephone>+98 44 3223 7078</telephone>
        <email>dr_kamrandehghan@yahoo.com</email>
        <affiliation>Oroumia University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Preterm infants weighting 1000-1500 g and less than 32 weeks’ gestational age at birth
Enrolled within 48 hours of birth</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Major congenital anomalies(Esophageal atresia,Omphalocele,Imperforate anus)
Major congenital heart malformations
Genetic anomalies(e.g Trisomy 21 or other trisomies)
Considered likely to die within 72 hours of birth
Death before minimal entral feeding(10-20cc/kg/day)
Parents from whom informed consent cannot be obtained
Sepsis in admission(CRP&gt;10mg/dl in 1st day of admission)
Asphyxia (grade II, III)
Maternal chorioamnionitis</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>P36.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Bacterial sepsis of newborn, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 42 preterm infants with a gestational age of less than 32 weeks and a weight of between 1,000-1,500 g and matched with clinical inclusion criteria for the study  randomly assigned and recived one drop  per kilogram of body weight of probiotic(Pedilact droplet of Zist takhmir Company) solution twice daily.</i_keyword>
      <i_keyword>Control group: 42 preterm infants with a gestational age of less than 32 weeks and a weight of between 1,000-1,500 g and matched with clinical inclusion criteria for the study randomly assigned and recived one drop  per kilogram of body weight of Dish water twice daily.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Late-onset sepsis. Timepoint: Baseline(admission), weekly and when clinical sepsis suspected. Method of measurement: Measurement of C-Reactive Protein and clinical clinical evaluation.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Necrotizing enterocolitis. Timepoint: On admission, every week, when symptoms of Necrotizing enterocolitis are diagnosed. Method of measurement: Clinical evaluation based on Bell's Criteria.</sec_outcome>
      <sec_outcome>Duration of primary hospitalization. Timepoint: Time of discharge. Method of measurement: Count the number of hospitalization days.</sec_outcome>
      <sec_outcome>The number of days the infant takes to complete entral feeding(120mL/kg per day). Timepoint: During the study period. Method of measurement: number of days until an infant to eat 120mL / kg per day of milk.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Oroumia University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-02-08</approval_date>
        <contact_name>Ethic committee of Urmia University of Medical Sciences</contact_name>
        <contact_address>Urmia university of medical sciences-Resalat Blvd-Emergency Alley. Urmia   Vest Azarbaijan  Iran, Islamic Republic Of Urmia West Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
